77 related articles for article (PubMed ID: 9887670)
1. [Critical evaluation of a cost-effectiveness analysis].
Sendi PP; Bucher HC; Steurer J
Praxis (Bern 1994); 1998 Dec; 87(49):1695-702. PubMed ID: 9887670
[No Abstract] [Full Text] [Related]
2. Screening for mild thyroid failure.
Wadland WC
J Fam Pract; 1996 Nov; 43(5):441-2. PubMed ID: 8917141
[No Abstract] [Full Text] [Related]
3. The cost-effectiveness of universal screening in pregnancy for subclinical hypothyroidism.
Thung SF; Funai EF; Grobman WA
Am J Obstet Gynecol; 2009 Mar; 200(3):267.e1-7. PubMed ID: 19114278
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
5. [QALY or willingness to pay?].
Steurer J
Praxis (Bern 1994); 1999 Feb; 88(8):333-8. PubMed ID: 10097643
[No Abstract] [Full Text] [Related]
6. The cost-effectiveness of screening for latent tuberculosis infection.
Taylor Z
Int J Tuberc Lung Dis; 2000 Dec; 4(12 Suppl 2):S127-33. PubMed ID: 11144542
[No Abstract] [Full Text] [Related]
7. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.
Plunkett BA; Grobman WA
Am J Obstet Gynecol; 2005 Apr; 192(4):1153-61. PubMed ID: 15846195
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
[TBL] [Abstract][Full Text] [Related]
9. [Neonatal screening for metabolic diseases--a task without priority in the Norwegian health policy?].
Pettersen RD; Saugstad OD; Lie SO
Tidsskr Nor Laegeforen; 1995 Feb; 115(5):607-8. PubMed ID: 7900116
[TBL] [Abstract][Full Text] [Related]
10. The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women.
Gift TL; Gaydos CA; Kent CK; Marrazzo JM; Rietmeijer CA; Schillinger JA; Dunne EF
Sex Transm Dis; 2008 Nov; 35(11 Suppl):S66-75. PubMed ID: 18830137
[TBL] [Abstract][Full Text] [Related]
11. [A cost-benefit evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism].
Gu X; Wang J; Ye J; Cheng X
Zhonghua Yu Fang Yi Xue Za Zhi; 2000 May; 34(3):147-9. PubMed ID: 11860921
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.
Lin OS; Keeffe EB; Sanders GD; Owens DK
Aliment Pharmacol Ther; 2004 Jun; 19(11):1159-72. PubMed ID: 15153169
[TBL] [Abstract][Full Text] [Related]
13. [Economic approach to breast cancer screening in Belgium].
Grivegnée AR; Autier P
Rev Med Brux; 2001 Sep; 22(4):A277-81. PubMed ID: 11680188
[TBL] [Abstract][Full Text] [Related]
14. Screening for colorectal cancer: which test can we afford?
Lansdorp-Vogelaar I; van Ballegooijen M; Kuipers EJ
Z Gastroenterol; 2008 Apr; 46 Suppl 1():S38-40. PubMed ID: 18368641
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness of screening for HIV.
da Silveira E
N Engl J Med; 2005 May; 352(20):2137-9; author reply 2137-9. PubMed ID: 15906436
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate.
Mobley LR; Hoerger TJ; Wittenborn JS; Galuska DA; Rao JK
Med Decis Making; 2006; 26(2):194-206. PubMed ID: 16525173
[TBL] [Abstract][Full Text] [Related]
17. [Routine health screening, yes or no? It depends].
Köck CM
Wien Klin Wochenschr; 1997 Mar; 109(5):141-4. PubMed ID: 9173661
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines.
Hayashino Y; Shimbo T; Tsujii S; Ishii H; Kondo H; Nakamura T; Nagata-Kobayashi S; Fukui T
Int J Cardiol; 2007 May; 118(1):88-96. PubMed ID: 16949690
[TBL] [Abstract][Full Text] [Related]
19. [Health economics analysis of colorectal screening].
Boncz I; Sebestyén A; Dózsa C; Pál M; Sándor J; Palásti J; Betlehem J; Ember I
Magy Onkol; 2004; 48(2):111-5. PubMed ID: 15351803
[TBL] [Abstract][Full Text] [Related]
20. The costs and benefits of enhanced depression care to employers.
Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
